Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-10-11

Clinical Trial Update: Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain [Phase 4]

View source ↗

Summary

A Phase 4 safety and efficacy study of OROS hydromorphone for cancer-related pain was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OROS Hydromorphone (hydromorphone)

Snippet

Sponsor: Janssen Pharmaceutica | Conditions: Pain | Phase 4 | Status: TERMINATED | Results posted: 2013-10-11